Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1997): Carrasco JM+, Ann Pharmacother 31, 120
(1997): Movin T+, Foot Ankle Int 18, 297 (2 cases)
(1997): Peyrade F+, Presse Med (French) 26, 1489
(1997): Poon CC+, Med J Aust 166, 665
(1997): Shinohara YT+, J Rheumatol 24, 238
(1996): Hugo-Persson M, Lakartidningen (Swedish) 93, 1520
(1996): Jagose JT+, NZMedJ109, 471
(1996): McGarvey WC+, Foot Ankle Int 17, 496
(1993): Boulay I+, Ann Med Interne (Paris) (French) 144, 493
(1992): Lee TW+, Aust N Z J Med, 22, 500
CISATRACURIUM
Trade name: Nimbex (Abbott)
Indications: Adjunct to general anesthesia, relaxes skeletal
muscle
Category: Non-depolarizing neuromuscular blocker
Half-life: 22 minutes
Clinically important, potentially hazardous interactions
with: aminoglycosides, clindamycin, cyclopropane, enflurane,
halothane, isoflurane, methoxyflurane, piperacillin, rocuronium
Reactions
Skin
Rash (sic) (0.1%)
Other
Anaphylactoid reactions/Anaphylaxis
(2005): Dewachter P+, AnnFrAnesthReanim24(5), 543
(2005): Fraser BA+, Anaesth Intensive Care 33(6), 816
(2004): Sanchez Palacios A+, Allergol Immunopathol (Madr)
32(6), 352
(2003): Rieder J+, Anesth Analg 96(1), 301
(2002): Iannuzzi E+, Eur J Anaesthesiol 19(9), 691
(2001): Krombach J+, Anesth Analg 93(5), 1257
(2001): Legros CB+, Anesth Analg 92(3), 648
(2000): Briassoulis G+, Paediatr Anaesth 10(4), 429
(1999): Toh KW+, Anesth Analg 88(2), 462
(1997): Clendenen SR+, Anesthesiology 87(3), 690
Hypersensitivity
Myalgia/Myositis/Myopathy/Myotoxicity
(1998): Davis NA+, Crit Care Med 26(7), 1290
CISPLATIN
Synonym: CDDP
Trade names: Cisplatyl; Plasticin; Platiblastin; Platinex; Platinol
(Bristol-Myers Squibb); Platinol-AQ; Platistil
Indications: Carcinomas, lymphomas
Category: Alkylating agent; Antineoplastic
Half-life: α phase: 25–49 minutes; β phase: 58–73 hours
Clinically important, potentially hazardous interactions
with: aldesleukin, atenolol, chlorothiazide, methotrexate,
selenium, zinc
Reactions
Skin
Acral erythema
(1998): Vakalis D+, Br J Dermatol 139, 750
Actinic keratoses
(1987): Johnson TM+, JAmAcadDermatol17(2 Pt 1), 192
Allergic reactions (sic)
CISPLATIN 129
(2002): Cantu MG+, J Clin Oncol 20(5), 1232 (2%) (with
cyclophosphamide and doxorubicin)
Angioedema
(1984): Loehrer PJ+, AnnInternMed100, 704
(1983): Bronner AK+, JAmAcadDermatol9, 645 (1–5%)
(1981): Weiss RB+, AnnInternMed94, 66 (1–5%)
Dermatitis
(1996): Schena D+, Contact Dermatitis 34, 220
Diaphoresis
(1983): Bronner AK+, JAmAcadDermatol9, 645
Erythema
(2001): Robinson JB+, Gynecol Oncol 82(3), 550
(1983): Bronner AK+, JAmAcadDermatol9, 645
(1980): Vogl SE+, Cancer 45, 11
Exanthems
(2003): Lin XG+, Ai Zheng 22(4), 411 (with paclitaxel)
(1984): Loehrer PJ+, AnnInternMed100, 704
(1981): Weiss RB+, AnnInternMed94, 66 (1–5%)
(1980): Vogl SE+, Cancer 45, 11
Exfoliative dermatitis
(1994): Lee TC+, Mayo Clin Proc 69, 80
Facial edema
(1994): Lee TC+, Mayo Clin Proc 69, 80
Necrosis
(2006): Stijelja B+, Srp Arh Celok Lek 134(5-6), 244 (penis)
(1983): Leyden M+, Cancer Treat Rep 67, 199
Pigmentation
(2006): Yanagi T+, JAmAcadDermatol54(2), 362
(2002): Kim KJ+, Clin Exp Dermatol 27(2), 118
(1996): Al-Lamki Z+, Cancer 77, 1578
Pruritus
(2002): Koren C+, Am J Clin Oncol 25(6), 625
(2001): Robinson JB+, Gynecol Oncol 82(3), 550
(1994): Lee TC+, Mayo Clin Proc 69, 80 (passim)
(1983): Bronner AK+, JAmAcadDermatol9, 645 (1–5%)
(1981): Weiss RB+, AnnInternMed94, 66 (1–5%)
Pyoderma (verrucous)
(1982): Person JR+, Arch Dermatol 118, 336
Rash (sic)
(2002): Koren C+, Am J Clin Oncol 25(6), 625
Raynaud’s phenomenon
(1994): Gerl A, Anticancer Drugs 5(6), 607
(1992): Doll DC+, Semin Oncol 19(5), 580
(1992): Hansen SW, Dan Med Bull 39(5), 391 (with vinblastine &
bleomycin)
(1991): Heier MS+, Br J Cancer 63(4), 550 (with vinblastine &
bleomycin)
(1990): Bissett D+, Br J Cancer 62(4), 655
(1990): Hansen SW+, Ann Oncol 1(4), 289 (with vinblastine &
bleomycin)
(1989): Hansen SW+, J Clin Oncol 7(7), 940 (with vinblastine &
bleomycin)
(1988): Stefenelli T+, Eur Heart J 9(5), 552 (with vinblastine &
bleomycin)
(1986): Fossa SD+, Cancer 58(12), 2600
(1985): Vogelzang NJ+, Cancer 56(12), 2765 (with vinblastine &
bleomycin)
(1984): Davis TE+, Gynecol Oncol 1984 Sep 19(1), 46 (with
vinblastine & bleomycin)
(1984): Loehrer PJ+, AnnInternMed100, 704
(1981): Vogelzang NJ+, AnnInternMed95, 288
Stevens–Johnson syndrome
(1989): Brodsky A+, J Clin Pharmacol 29, 821
Urticaria
(1996): Schena D+, Contact Dermatitis 34, 220
(1994): Lee TC+, Mayo Clin Proc 69, 80 (passim)
(1983): Bronner AK+, JAmAcadDermatol9, 645 (1–5%)
(1981): Weiss RB+, AnnInternMed94, 66 (1–5%)
(1980): Vogl SE+, Cancer 45, 11